Clinical Hematology International
Volume 3, Issue 4, December 2021
1. The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience
Didier Blaise, Pierre Berger, Djamel Mokart, Jacques Camerlo, Emmanuelle Fougereau, Marc Giovannini, Gilles Houvenaeghel, Olivier Turrini, Christian Chabannon, Gilles Piana, Isabelle Brenot-Rossi, Agnès Tallet, Anthony Gonçalves, Aude Charbonnier, Norbert Vey, Sabrina Grossi, Patrice Viens
Pages: 119 - 129
During the COVID-19 pandemic, it was rapidly established that cancer patients have an increased risk of developing severe forms of the 2019 coronavirus disease (COVID-19) due to a backlog of cancer diagnostics and immunosuppressive treatments. Cancer centers had to quickly adapt to continue cancer therapies...
2. How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
Fiona Fernando, Harry Frederick Robertson, Sarah El-Zahab, Jiří Pavlů
Pages: 130 - 141
Over the last decade the use of measurable residual disease (MRD) diagnostics in adult acute lymphoblastic leukemia (ALL) has expanded from a limited number of study groups in Europe and the United States to a world-wide application. In this review, we summarize the advantages and drawbacks of the current...
Miguel A. Sanz, Eva Barragán
Pages: 142 - 152
In this article, we discuss the history of acute promyelocytic leukemia (APL) from the pre-therapeutic era, which began after its recognition by Hillestad in 1947 as a nosological entity, to the present day. It is a paradigmatic history that has transformed the “most malignant leukemia form” into the...
4. Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently
Francesco Saraceni, Ilaria Scortechini, Alessandro Fiorentini, Maria Vittoria Dubbini, Giorgia Mancini, Irene Federici, Francesca Romana Colaneri, Antonio Federico Lotito, Selene Guerzoni, Bruna Puglisi, Attilio Olivieri
Pages: 153 - 160
Despite the recent dramatic progress in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) therapy, allogeneic transplant remains a mainstay of treatment for patients with acute leukemia. The availability of novel compounds and low intensity chemotherapy regimens made it possible for...
5. Gastrointestinal Complications after Allogeneic Hematopoietic Stem Cell Transplant: A Multidisciplinary Approach with Early Endoscopic Evaluation
Giuseppe Tarantino, Francesco Saraceni, Giorgia Mancini, Monica Poiani, Luca Maroni, Gaia Goteri, Ilaria Scortechini, Alessandro Fiorentini, Maria Vittoria Dubbini, Francesco Marini, Luigi Daretti, Marco Marzioni, Emanuele Bendia, Antonio Benedetti, Attilio Olivieri
Pages: 161 - 168
Gastrointestinal complications (GICs) represent the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Differential diagnosis of GICs is of paramount importance since early and reliable identification of graft-versus-host disease (GVHD) is essential...